New legislation in Congress would prohibit limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions; drug companies, researchers, and health officials are trying to develop an overdose-reversal treatment that is more successful than naloxone against synthetic opioids; a Texas lawsuit seeking to strike down the Affordable Care Act is being opposed by 16 Democratic attorneys general.
New legislation in Congress would prohibit insurers or pharmacy benefit managers from limiting what pharmacists can tell patients about the cheapest way to pay for their prescriptions. According to The Detroit News, some prescriptions may be cheaper for customers if they pay in cash, rather than their insurance co-pay, but pharmacists were unable to tell them that. The legislation is being sponsored by Senators Debbie Stabenow, D-Michigan, and Susan Collins, R-Maine. Research has shown customers overpay for prescriptions 23% of the time.
Naloxone is widely used to reverse opioid overdoses, but it has limited success against synthetic opioids. With the use of synthetic opioids on the rise, drug companies, researchers, and health officials are trying to develop a new treatment that may replace naloxone in certain cases, reported STAT. One option being pursued is tweaking buprenorphine, which is currently used to treat addiction, but may also be able to reverse an overdose with some changes.
A Texas lawsuit seeking to strike down the Affordable Care Act (ACA) has strong opposition from 16 Democratic attorneys general (AGs), led by California AG Xavier Becerra. As a result, there is a showdown between red and blue states with 19 Republican-led states joining Texas’ case, according to The New York Times. Texas’ lawsuit claims the repeal of the individual mandate as part of the Republican tax bill means that the ACA is no longer valid.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen